1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Valsartan
        1.2.3 Irbesartan
        1.2.4 Candesartan Cilexetil
        1.2.5 Eprosartan
        1.2.6 Irbesartan
        1.2.7 Telmisartan
        1.2.8 losartan
        1.2.9 Olmesartan Medoxomil
        1.2.10 Allisartan isoproxil
    1.3 Market by Application
        1.3.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 High Blood Pressure
        1.3.3 Congestive Heart Failure
        1.3.4 Left Ventricular Hypertrophy
        1.3.5 Atherosclerosis
        1.3.6 Other
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Perspective (2017-2028)
    2.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Growth Trends by Region
        2.2.1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Historic Market Size by Region (2017-2022)
        2.2.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Region (2023-2028)
    2.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Dynamics
        2.3.1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Industry Trends
        2.3.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Drivers
        2.3.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Challenges
        2.3.4 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players by Revenue
        3.1.1 Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players by Revenue (2017-2022)
        3.1.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Players (2017-2022)
    3.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue
    3.4 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Concentration Ratio
        3.4.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue in 2021
    3.5 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players Head office and Area Served
    3.6 Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Solution and Service
    3.7 Date of Enter into Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Breakdown Data by Type
    4.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Historic Market Size by Type (2017-2022)
    4.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Type (2023-2028)
5 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Breakdown Data by Application
    5.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Historic Market Size by Application (2017-2022)
    5.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2017-2028)
    6.2 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type
        6.2.1 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2017-2022)
        6.2.2 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2023-2028)
        6.2.3 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type (2017-2028)
    6.3 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application
        6.3.1 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2017-2022)
        6.3.2 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2023-2028)
        6.3.3 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2017-2028)
    6.4 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country
        6.4.1 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2017-2022)
        6.4.2 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2023-2028)
        6.4.3 U.S.
        6.4.4 Canada
7 Europe
    7.1 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2017-2028)
    7.2 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type
        7.2.1 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2017-2022)
        7.2.2 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2023-2028)
        7.2.3 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type (2017-2028)
    7.3 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application
        7.3.1 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2017-2022)
        7.3.2 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2023-2028)
        7.3.3 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2017-2028)
    7.4 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country
        7.4.1 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2017-2022)
        7.4.2 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2023-2028)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2017-2028)
    8.2 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type
        8.2.1 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2023-2028)
        8.2.3 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type (2017-2028)
    8.3 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application
        8.3.1 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2023-2028)
        8.3.3 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2017-2028)
    8.4 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Region
        8.4.1 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Region (2023-2028)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2017-2028)
    9.2 Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type
        9.2.1 Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2017-2022)
        9.2.2 Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2023-2028)
        9.2.3 Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type (2017-2028)
    9.3 Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application
        9.3.1 Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2017-2022)
        9.3.2 Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2023-2028)
        9.3.3 Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2017-2028)
    9.4 Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country
        9.4.1 Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2017-2022)
        9.4.2 Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2023-2028)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2017-2028)
    10.2 Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type
        10.2.1 Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2023-2028)
        10.2.3 Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type (2017-2028)
    10.3 Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application
        10.3.1 Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2023-2028)
        10.3.3 Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2017-2028)
    10.4 Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country
        10.4.1 Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2023-2028)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 Pfizer
        11.1.1 Pfizer Company Details
        11.1.2 Pfizer Business Overview
        11.1.3 Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
        11.1.4 Pfizer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
        11.1.5 Pfizer Recent Developments
    11.2 Novartis
        11.2.1 Novartis Company Details
        11.2.2 Novartis Business Overview
        11.2.3 Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
        11.2.4 Novartis Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
        11.2.5 Novartis Recent Developments
    11.3 Merck
        11.3.1 Merck Company Details
        11.3.2 Merck Business Overview
        11.3.3 Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
        11.3.4 Merck Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
        11.3.5 Merck Recent Developments
    11.4 AstraZeneca
        11.4.1 AstraZeneca Company Details
        11.4.2 AstraZeneca Business Overview
        11.4.3 AstraZeneca Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
        11.4.4 AstraZeneca Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
        11.4.5 AstraZeneca Recent Developments
    11.5 Jhonson and Johnson
        11.5.1 Jhonson and Johnson Company Details
        11.5.2 Jhonson and Johnson Business Overview
        11.5.3 Jhonson and Johnson Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
        11.5.4 Jhonson and Johnson Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
        11.5.5 Jhonson and Johnson Recent Developments
    11.6 Eli Lilly
        11.6.1 Eli Lilly Company Details
        11.6.2 Eli Lilly Business Overview
        11.6.3 Eli Lilly Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
        11.6.4 Eli Lilly Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
        11.6.5 Eli Lilly Recent Developments
    11.7 Sanofi
        11.7.1 Sanofi Company Details
        11.7.2 Sanofi Business Overview
        11.7.3 Sanofi Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
        11.7.4 Sanofi Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
        11.7.5 Sanofi Recent Developments
    11.8 Bristol-Myers Squibb
        11.8.1 Bristol-Myers Squibb Company Details
        11.8.2 Bristol-Myers Squibb Business Overview
        11.8.3 Bristol-Myers Squibb Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
        11.8.4 Bristol-Myers Squibb Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
        11.8.5 Bristol-Myers Squibb Recent Developments
    11.9 Bayer
        11.9.1 Bayer Company Details
        11.9.2 Bayer Business Overview
        11.9.3 Bayer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
        11.9.4 Bayer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
        11.9.5 Bayer Recent Developments
    11.10 GSK
        11.10.1 GSK Company Details
        11.10.2 GSK Business Overview
        11.10.3 GSK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
        11.10.4 GSK Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
        11.10.5 GSK Recent Developments
    11.11 Teva Pharmaceutical
        11.11.1 Teva Pharmaceutical Company Details
        11.11.2 Teva Pharmaceutical Business Overview
        11.11.3 Teva Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
        11.11.4 Teva Pharmaceutical Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
        11.11.5 Teva Pharmaceutical Recent Developments
    11.12 Shenzhen Salubris Pharmaceuticals 
        11.12.1 Shenzhen Salubris Pharmaceuticals  Company Details
        11.12.2 Shenzhen Salubris Pharmaceuticals  Business Overview
        11.12.3 Shenzhen Salubris Pharmaceuticals  Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
        11.12.4 Shenzhen Salubris Pharmaceuticals  Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
        11.12.5 Shenzhen Salubris Pharmaceuticals  Recent Developments
    11.13 Sun Pharmaceutical
        11.13.1 Sun Pharmaceutical Company Details
        11.13.2 Sun Pharmaceutical Business Overview
        11.13.3 Sun Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
        11.13.4 Sun Pharmaceutical Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
        11.13.5 Sun Pharmaceutical Recent Developments
    11.14 Mylan
        11.14.1 Mylan Company Details
        11.14.2 Mylan Business Overview
        11.14.3 Mylan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
        11.14.4 Mylan Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
        11.14.5 Mylan Recent Developments
    11.15 Alembic Pharmaceuticals
        11.15.1 Alembic Pharmaceuticals Company Details
        11.15.2 Alembic Pharmaceuticals Business Overview
        11.15.3 Alembic Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
        11.15.4 Alembic Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
        11.15.5 Alembic Pharmaceuticals Recent Developments
    11.16 Lupin
        11.16.1 Lupin Company Details
        11.16.2 Lupin Business Overview
        11.16.3 Lupin Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
        11.16.4 Lupin Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
        11.16.5 Lupin Recent Developments
    11.17 Aurobindo Pharma
        11.17.1 Aurobindo Pharma Company Details
        11.17.2 Aurobindo Pharma Business Overview
        11.17.3 Aurobindo Pharma Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
        11.17.4 Aurobindo Pharma Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
        11.17.5 Aurobindo Pharma Recent Developments
    11.18 Amneal Pharmaceuticals
        11.18.1 Amneal Pharmaceuticals Company Details
        11.18.2 Amneal Pharmaceuticals Business Overview
        11.18.3 Amneal Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
        11.18.4 Amneal Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
        11.18.5 Amneal Pharmaceuticals Recent Developments
    11.19 Boehringer Ingelheim
        11.19.1 Boehringer Ingelheim Company Details
        11.19.2 Boehringer Ingelheim Business Overview
        11.19.3 Boehringer Ingelheim Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
        11.19.4 Boehringer Ingelheim Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
        11.19.5 Boehringer Ingelheim Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer
                  
              

                

                 
List of Tables
    Table 1. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of Valsartan
    Table 3. Key Players of Irbesartan
    Table 4. Key Players of Candesartan Cilexetil
    Table 5. Key Players of Eprosartan
    Table 6. Key Players of Irbesartan
    Table 7. Key Players of Telmisartan
    Table 8. Key Players of losartan
    Table 9. Key Players of Olmesartan Medoxomil
    Table 10. Key Players of Allisartan isoproxil
    Table 11. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
    Table 12. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 13. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Region (2017-2022) & (US$ Million)
    Table 14. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Region (2017-2022)
    Table 15. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 16. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Region (2023-2028)
    Table 17. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Trends
    Table 18. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Drivers
    Table 19. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Challenges
    Table 20. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Restraints
    Table 21. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Players (2017-2022) & (US$ Million)
    Table 22. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Share by Players (2017-2022)
    Table 23. Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist as of 2021)
    Table 24. Ranking of Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Companies by Revenue (US$ Million) in 2021
    Table 25. Global 5 Largest Players Market Share by Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (CR5 and HHI) & (2017-2022)
    Table 26. Key Players Headquarters and Area Served
    Table 27. Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Solution and Service
    Table 28. Date of Enter into Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market
    Table 29. Mergers & Acquisitions, Expansion Plans
    Table 30. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2017-2022) & (US$ Million)
    Table 31. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Type (2017-2022)
    Table 32. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 33. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Type (2023-2028)
    Table 34. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2017-2022) & (US$ Million)
    Table 35. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Share by Application (2017-2022)
    Table 36. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 37. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Share by Application (2023-2028)
    Table 38. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2017-2022) & (US$ Million)
    Table 39. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2023-2028) & (US$ Million)
    Table 40. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2017-2022) & (US$ Million)
    Table 41. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2023-2028) & (US$ Million)
    Table 42. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2017-2022) & (US$ Million)
    Table 43. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2023-2028) & (US$ Million)
    Table 44. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2017-2022) & (US$ Million)
    Table 45. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2023-2028) & (US$ Million)
    Table 46. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2017-2022) & (US$ Million)
    Table 47. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2023-2028) & (US$ Million)
    Table 48. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2017-2022) & (US$ Million)
    Table 49. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2023-2028) & (US$ Million)
    Table 50. Asia Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2017-2022) & (US$ Million)
    Table 51. Asia Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2023-2028) & (US$ Million)
    Table 52. Asia Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2017-2022) & (US$ Million)
    Table 53. Asia Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2023-2028) & (US$ Million)
    Table 54. Asia Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Region (2017-2022) & (US$ Million)
    Table 55. Asia Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Region (2023-2028) & (US$ Million)
    Table 56. Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2017-2022) & (US$ Million)
    Table 57. Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2023-2028) & (US$ Million)
    Table 58. Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2017-2022) & (US$ Million)
    Table 59. Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2023-2028) & (US$ Million)
    Table 60. Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2017-2022) & (US$ Million)
    Table 61. Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2023-2028) & (US$ Million)
    Table 62. Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2017-2022) & (US$ Million)
    Table 63. Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2023-2028) & (US$ Million)
    Table 64. Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2017-2022) & (US$ Million)
    Table 65. Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2023-2028) & (US$ Million)
    Table 66. Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2017-2022) & (US$ Million)
    Table 67. Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country (2023-2028) & (US$ Million)
    Table 68. Pfizer Company Details
    Table 69. Pfizer Business Overview
    Table 70. Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 71. Pfizer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 72. Pfizer Recent Developments
    Table 73. Novartis Company Details
    Table 74. Novartis Business Overview
    Table 75. Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 76. Novartis Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 77. Novartis Recent Developments
    Table 78. Merck Company Details
    Table 79. Merck Business Overview
    Table 80. Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 81. Merck Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 82. Merck Recent Developments
    Table 83. AstraZeneca Company Details
    Table 84. AstraZeneca Business Overview
    Table 85. AstraZeneca Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 86. AstraZeneca Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 87. AstraZeneca Recent Developments
    Table 88. Jhonson and Johnson Company Details
    Table 89. Jhonson and Johnson Business Overview
    Table 90. Jhonson and Johnson Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 91. Jhonson and Johnson Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 92. Jhonson and Johnson Recent Developments
    Table 93. Eli Lilly Company Details
    Table 94. Eli Lilly Business Overview
    Table 95. Eli Lilly Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 96. Eli Lilly Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 97. Eli Lilly Recent Developments
    Table 98. Sanofi Company Details
    Table 99. Sanofi Business Overview
    Table 100. Sanofi Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 101. Sanofi Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 102. Sanofi Recent Developments
    Table 103. Bristol-Myers Squibb Company Details
    Table 104. Bristol-Myers Squibb Business Overview
    Table 105. Bristol-Myers Squibb Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 106. Bristol-Myers Squibb Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 107. Bristol-Myers Squibb Recent Developments
    Table 108. Bayer Company Details
    Table 109. Bayer Business Overview
    Table 110. Bayer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 111. Bayer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 112. Bayer Recent Developments
    Table 113. GSK Company Details
    Table 114. GSK Business Overview
    Table 115. GSK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 116. GSK Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 117. GSK Recent Developments
    Table 118. Teva Pharmaceutical Company Details
    Table 119. Teva Pharmaceutical Business Overview
    Table 120. Teva Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 121. Teva Pharmaceutical Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 122. Teva Pharmaceutical Recent Developments
    Table 123. Shenzhen Salubris Pharmaceuticals  Company Details
    Table 124. Shenzhen Salubris Pharmaceuticals  Business Overview
    Table 125. Shenzhen Salubris Pharmaceuticals  Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 126. Shenzhen Salubris Pharmaceuticals  Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 127. Shenzhen Salubris Pharmaceuticals  Recent Developments
    Table 128. Sun Pharmaceutical Company Details
    Table 129. Sun Pharmaceutical Business Overview
    Table 130. Sun Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 131. Sun Pharmaceutical Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 132. Sun Pharmaceutical Recent Developments
    Table 133. Mylan Company Details
    Table 134. Mylan Business Overview
    Table 135. Mylan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 136. Mylan Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 137. Mylan Recent Developments
    Table 138. Alembic Pharmaceuticals Company Details
    Table 139. Alembic Pharmaceuticals Business Overview
    Table 140. Alembic Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 141. Alembic Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 142. Alembic Pharmaceuticals Recent Developments
    Table 143. Lupin Company Details
    Table 144. Lupin Business Overview
    Table 145. Lupin Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 146. Lupin Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 147. Lupin Recent Developments
    Table 148. Aurobindo Pharma Company Details
    Table 149. Aurobindo Pharma Business Overview
    Table 150. Aurobindo Pharma Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 151. Aurobindo Pharma Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 152. Aurobindo Pharma Recent Developments
    Table 153. Amneal Pharmaceuticals Company Details
    Table 154. Amneal Pharmaceuticals Business Overview
    Table 155. Amneal Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 156. Amneal Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 157. Amneal Pharmaceuticals Recent Developments
    Table 158. Boehringer Ingelheim Company Details
    Table 159. Boehringer Ingelheim Business Overview
    Table 160. Boehringer Ingelheim Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product
    Table 161. Boehringer Ingelheim Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022) & (US$ Million)
    Table 162. Boehringer Ingelheim Recent Developments
    Table 163. Research Programs/Design for This Report
    Table 164. Key Data Information from Secondary Sources
    Table 165. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type: 2021 VS 2028
    Figure 2. Valsartan Features
    Figure 3. Irbesartan Features
    Figure 4. Candesartan Cilexetil Features
    Figure 5. Eprosartan Features
    Figure 6. Irbesartan Features
    Figure 7. Telmisartan Features
    Figure 8. losartan Features
    Figure 9. Olmesartan Medoxomil Features
    Figure 10. Allisartan isoproxil Features
    Figure 11. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application: 2021 VS 2028
    Figure 12. High Blood Pressure Case Studies
    Figure 13. Congestive Heart Failure Case Studies
    Figure 14. Left Ventricular Hypertrophy Case Studies
    Figure 15. Atherosclerosis Case Studies
    Figure 16. Other Case Studies
    Figure 17. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Report Years Considered
    Figure 18. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 19. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 20. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Region: 2021 VS 2028
    Figure 21. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Players in 2021
    Figure 22. Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist as of 2021)
    Figure 23. The Top 10 and 5 Players Market Share by Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue in 2021
    Figure 24. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY (2017-2028) & (US$ Million)
    Figure 25. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Market Share by Type (2017-2028)
    Figure 26. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Market Share by Application (2017-2028)
    Figure 27. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Share by Country (2017-2028)
    Figure 28. United States Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. Canada Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY (2017-2028) & (US$ Million)
    Figure 31. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Market Share by Type (2017-2028)
    Figure 32. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Market Share by Application (2017-2028)
    Figure 33. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Share by Country (2017-2028)
    Figure 34. Germany Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. France Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. U.K. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 37. Italy Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 38. Russia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. Nordic Countries Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY (2017-2028) & (US$ Million)
    Figure 41. Asia Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Market Share by Type (2017-2028)
    Figure 42. Asia Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Market Share by Application (2017-2028)
    Figure 43. Asia Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Share by Region (2017-2028)
    Figure 44. China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 45. Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 46. South Korea Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 47. Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 48. India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 49. Australia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
    Figure 50. Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY (2017-2028) & (US$ Million)
    Figure 51. Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Market Share by Type (2017-2028)
    Figure 52. Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Market Share by Application (2017-2028)
    Figure 53. Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Share by Country (2017-2028)
    Figure 54. Mexico Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 55. Brazil Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 56. Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY (2017-2028) & (US$ Million)
    Figure 57. Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Market Share by Type (2017-2028)
    Figure 58. Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Market Share by Application (2017-2028)
    Figure 59. Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Share by Country (2017-2028)
    Figure 60. Turkey Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 61. Saudi Arabia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 62. UAE Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 63. Pfizer Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 64. Novartis Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 65. Merck Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 66. AstraZeneca Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 67. Jhonson and Johnson Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 68. Eli Lilly Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 69. Sanofi Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 70. Bristol-Myers Squibb Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 71. Bayer Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 72. GSK Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 73. Teva Pharmaceutical Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 74. Shenzhen Salubris Pharmaceuticals  Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 75. Sun Pharmaceutical Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 76. Mylan Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 77. Alembic Pharmaceuticals Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 78. Lupin Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 79. Aurobindo Pharma Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 80. Amneal Pharmaceuticals Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 81. Boehringer Ingelheim Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2017-2022)
    Figure 82. Bottom-up and Top-down Approaches for This Report
    Figure 83. Data Triangulation
    Figure 84. Key Executives Interviewed